CVS Health (NYSE: CVS) stock soared 5.11% in pre-market trading on Wednesday following the release of its third-quarter earnings report, which exceeded analysts' expectations and prompted the company to raise its full-year guidance.

The healthcare giant reported adjusted earnings per share of $1.60 for Q3, significantly beating the Wall Street consensus estimate of $1.37. Total revenue for the quarter climbed 7.8% year-over-year to $102.87 billion, surpassing analysts' projections of $98.85 billion. The strong performance was driven by improved results across its business segments, particularly in the Health Care Benefits division.

In light of the robust quarterly results, CVS Health raised its full-year 2025 adjusted earnings per share guidance to a range of $6.55 to $6.65, up from the previous forecast of $6.30 to $6.40. This upward revision reflects the company's confidence in its ongoing operational improvements and growth strategies. Additionally, CVS updated its cash flow from operations guidance to a range of $7.5 billion to $8.0 billion for the full year.